Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation
Oncotarget, Volume 5, No. 10, Year 2014
Notification
URL copied to clipboard!
Description
Inflammation is an important component of various cancers and its inflammatory cells and mediators have been shown to have prognostic potential. Tumor-infiltrating mast cells can promote tumor growth and angiogenesis, but the mechanism of mast cell activation is unclear. In earlier studies, we demonstrated that immunoglobulin free light chains (FLC) can trigger mast cells in an antigen-specific manner. Increased expression of FLC was observed within stroma of various human cancers including those of breast, colon, lung, pancreas, kidney and skin, and FLC expression co-localized with areas of mast cell infiltration. In a large cohort of breast cancer patients, FLC expression was shown associated with basal-like cancers with an aggressive phenotype. Moreover, lambda FLC was found expressed in areas of inflammatory infiltration and its expression was significantly associated with poor clinical outcome. Functional importance of FLCs was shown in a murine B16F10 melanoma model, where inhibition of FLC-mediated mast cell activation strongly reduced tumor growth. Collectively, this study identifies FLCs as a ligand in the pro-tumorigenic activation of mast cells. Blocking this pathway may open new avenues for the inhibition of tumor growth, while immunohistochemical staining of FLC may be helpful in the diagnosis and prognosis of cancer. © 2008-2014 Impact Journals, LLC.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC4102799/bin/oncotarget-05-3159-s001.pdf
Authors & Co-Authors
Kormelink, Tom Groot
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Powe, Desmond George
United Kingdom, Nottingham
Queen's Medical Centre
United Kingdom, Nottingham
Nottingham Trent University
Kuijpers, Sylvia A.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Abudukelimu, Abulikemu
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Fens, Marcel H.A.M.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Pieters, Ebel H.E.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Kassing-van der Ven, Willemiek W.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Habashy, Hany Onsy
Egypt, Mansoura
Faculty of Medicine
Ellis, Ian O.
United Kingdom, Nottingham
Nottingham University Hospitals Nhs Trust
Blokhuis, Bart R.J.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Thio, Marco
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Hennink, Wim E.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Storm, Gert A.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Redegeld, F. A.M.
Netherlands, Utrecht
Utrechts Instituut Voor Farmaceutische Wetenschappen
Schiffelers, Raymond Michel
Netherlands, Utrecht
University Medical Center Utrecht
Statistics
Citations: 37
Authors: 15
Affiliations: 6
Identifiers
Doi:
10.18632/oncotarget.1868
e-ISSN:
19492553
Research Areas
Cancer
Study Design
Cohort Study